Durable clinical benefit to trastuzumab and chemotherapy in a patient with metastatic colon adenocarcinoma harboring ERBB2 amplification

Somatic ERBB2 amplification or activating mutations occur in approximately 2–5% of metastatic colorectal adenocarcinomas and are presumed to be oncogenic drivers, but limited evidence exists to suggest these lesions are sensitive to targeted monotherapy in patients. Here we present the case of a pat...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncoscience
Hlavní autoři: Disel, Umut, Germain, Alexis, Yilmazel, Bahar, Abali, Huseyin, Bolat, Filiz Aka, Yelensky, Roman, Elvin, Julia A., Lipson, Doron, Chmielecki, Juliann, Wang, Kai, Stephens, Philip J., Ross, Jeffrey S., Miller, Vincent A., Ali, Siraj M., George, Thomas J.
Médium: Artigo
Jazyk:Inglês
Vydáno: Impact Journals LLC 2015
Témata:
Case Report
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4506361/
https://ncbi.nlm.nih.gov/pubmed/26244165
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky